转化过的EGFR突变腺癌来源的小细胞肺癌（tSCLC）是一种罕见且侵袭性的肺癌形式，当肿瘤对EGFR靶向治疗产生抗药性并且癌细胞获得额外的基因组变异导致其转化为SCLC时会发生。tSCLC的治疗尚未确立，推荐的大多数是对于原发性SCLC的化疗方案。然而，这些治疗方法的效果令人失望，目前正在开发新型抗癌药物和免疫治疗方法。基于患者来源的细胞系是前期和转化研究的关键工具，但tSCLC的细胞系目前尚未在细胞库中公开提供。本研究的目的是建立和表征一个新的tSCLC细胞系。我们成功建立了一个细胞系，命名为BMC-PDC-019，该细胞系来源于一位58岁的女性患者的淋巴结活检组织，该患者的肿瘤为EGFR突变的肺腺癌，已经发展为afatinib耐药。肿瘤样本和细胞系表达了SCLC标志物CD56和synaptophysin的典型特征。BMC-PDC-019细胞的倍增时间为48小时。我们使用BMC-PDC-019细胞对当前用于原发性SCLC的抗癌药物的一系列抑制增殖效果进行了研究。我们得出结论，BMC-PDC-019将成为前期和转化研究的有用工具。©2023. 作者授予日本人类细胞学会独家许可。

Transformed small-cell lung cancer (tSCLC) from EGFR-mutant adenocarcinoma is a rare and aggressive form of lung cancer that can occur when the tumor develops resistance to EGFR targeted therapy and the cancer cells acquire additional genomic alterations that cause them to transform into SCLC. Treatment for tSCLC has not been established yet, and chemotherapy regimens for de novo SCLC are mostly recommended. However, these treatments showed disappointing outcome, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for pre-clinical and translational research, but cell line models for tSCLC are not publicly available from cell banks. The aim of this study was to establish and characterize a novel cell line for tSCLC. Using a lymph-node biopsy tissue from a 58-year-old female patient, whose tumor was EGFR-mutant lung adenocarcinoma progressed on afatinib, we successfully established a cell line, named BMC-PDC-019. The tumor sample and cell line showed a typical expression of SCLC markers, such as CD56 and synaptophysin. The population doubling-time of BMC-PDC-019 cells was 48 h. We examined a range of proliferation-inhibiting effects of anti-cancer drugs currently used for de novo SCLC, using BMC-PDC-019 cells. We concluded that BMC-PDC-019 would be a useful tool for pre-clinical and translational research.© 2023. The Author(s) under exclusive licence to Japan Human Cell Society.